SciELO - Scientific Electronic Library Online

 
vol.30 issue1Non-neoplasic osteomalacia in ColombiaAnálisis of health research in Santander: Role of the Instituto Colombiano de Investigaciones Biomédicas author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Medica Colombiana

Print version ISSN 0120-2448

Abstract

NIETO, Iván  and  MAHECHA, Patricia. Association between hyperphosphatemia and mortality in patients with terminal chronic renal insuficiency in renal function replacement therapy with peritoneal dyalisis or hemodialysis: A study of the Renal Unit in Villavicencio, 1999-2003. Acta Med Colomb [online]. 2005, vol.30, n.1, pp.14-18. ISSN 0120-2448.

Objective: to evaluate the risk of mortality in patients with renal chronic disease stage V with increased serum phosphorus levels to more than 6.5 mg%. Design: retrospective cohort with 273 patients in dialysis, 70% in peritoneal dialysis and 30% in hemodialysis between 1999-2003 in a single dialysis center in Villavicencio (Colombia). Methods: the mortality rate for the patients with increased phosphorus levels to more than de 6.5 mg% was calculated and the survival analysis was made with the Kaplan-Meier method. Results: the mean of age at the beginning of dialysis was 52.7 years, 30.1% diabetics, 46.2% high blood pressure; the mean phosphorus level was 4.73 mg%, mean serum calcium 9.05 mg% and PTHi 173, 7 UI/ml. 98 death cases were recorded. The survival curves for the patients with mean phosphorus > 6.5 mg% showed a Log Rank 3.9 (p=0.048) and a mortality rate in 1.32 (IC 95% 1.08-1.63). For the subjects with increased phosphorus levels to more than 5.5 mg% there were no statistically significant differences p=0.0785), with a mortality rate 1.12 (IC 95% 0.93-1.35). The 4.3% of the subjects showed phosphorus increase of more than 6.5 mg%. Conclusions: hyperphosphatemia (>6.5 mg%) is a risk factor for mortality in end stage renal disease (stage V) as well as in renal replacement therapy. It is recommended to maintain the level of phosphorus below 5.5 mg% to reduce the increased risk of death.

Keywords : hyperphosphatemia; renal chronic disease; peritoneal dialysis; hemodialysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License